Cargando…
Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study
FLU-v, developed by PepTcell (SEEK), is a peptide vaccine aiming to provide a broadly protective cellular immune response against influenza A and B. A randomized, double-blind, placebo-controlled, single-center, phase IIb efficacy and safety trial was conducted. One hundred and fifty-three healthy i...
Autores principales: | Pleguezuelos, Olga, James, Emma, Fernandez, Ana, Lopes, Victor, Rosas, Luz Angela, Cervantes-Medina, Adriana, Cleath, Jason, Edwards, Kristina, Neitzey, Dana, Gu, Wenjuan, Hunsberger, Sally, Taubenberger, Jeffery K., Stoloff, Gregory, Memoli, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069936/ https://www.ncbi.nlm.nih.gov/pubmed/32194999 http://dx.doi.org/10.1038/s41541-020-0174-9 |
Ejemplares similares
-
FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay
por: Oftung, Fredrik, et al.
Publicado: (2022) -
2750. Sequential Influenza A H1N1 and Influenza A H3N2 Challenge Infections in Healthy Volunteers
por: Han, Alison, et al.
Publicado: (2019) -
Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial
por: van Doorn, Eva, et al.
Publicado: (2017) -
1522. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model
por: Han, Alison, et al.
Publicado: (2020) -
H5Nx Panzootic Bird Flu—Influenza’s Newest Worldwide Evolutionary Tour
por: Taubenberger, Jeffery K., et al.
Publicado: (2017)